Acetylcholine Accumulation
Acetylcholine Accumulation - Related Videos
06:39
Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders
0 Views •
Cited by 36 •
2016
Intracoronary acetylcholine testing has been established for the assessment of epicardial coronary spasm more than 30 years ago. Recently, the focus has shifted towards the microcirculation and it has been shown that microvascular spasm can be detected using ACH-testing. This article describes the ACH-test and its implementation in daily routine.
10:04
Local Application of Drugs to Study Nicotinic Acetylcholine Receptor Function in Mouse Brain Slices
0 Views •
Cited by 23 •
2012
In this paper, we describe a useful method to study ligand-gated ion channel function in neurons of acutely isolated brain slices. This method involves the use of a drug-filled micropipette for local application of drugs to neurons recorded using standard patch clamp techniques.
01:27
Cost Accumulation and Flow
0 Views •
2026
In manufacturing, production costs are accumulated and tracked to understand how resources are consumed and how they contribute to the final product. This process, known as cost accumulation, involves recording material, labor, and overhead costs and linking them to specific cost objects, such as individual products or production processes.Costs flow through inventory accounts in a sequence that mirrors the physical movement of goods. Initially, raw materials are recorded in the raw materials...
07:59
Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
0 Views •
Cited by 3 •
2022
This protocol presents the acetylcholine rechallenge after nitroglycerine as an add-on procedure to spasm provocation testing. The purpose of this technique is to unmask co-existing microvascular spasm in patients with epicardial spasm and to assess the protective efficacy of nitroglycerine on a per-patient level to guide medical therapy.
04:02
An Assay to Measure the Accumulation of a Fluorescent Antibiotic Probe in Bacterial Cells
0 Views •
2025
This video demonstrates an assay to measure the accumulation of a fluorescent antibiotic probe in bacterial cells. Exposure to an efflux pump inhibitor disrupts the transmembrane proton gradient in bacterial cells, upon which a fluorophore-conjugated antibiotic is added. Inhibition of efflux pumps due to the disrupted proton gradient causes accumulation of the antibiotic inside the bacteria. Bacterial cells are lysed, and the fluorescence intensity is measured to confirm antibiotic accumulation.
FAQs
Acetylcholine accumulation prolongs cholinergic receptor activation because inhibited acetylcholinesterase no longer rapidly hydrolyzes the transmitter. The resulting signal is not a brief event confined to normal neurotransmission; stimulation can continue at synapses and neuromuscular junctions. This provides the mechanistic link between enzyme inhibition and disrupted signaling in pharmacological and toxicological settings.
These receptor classes matter because excess acetylcholine can maintain stimulation of both rather than selectively changing one receptor pathway. Considering muscarinic and nicotinic signaling together helps pharmacologists interpret the broad consequences of cholinergic overactivation and distinguish receptor-level effects from the upstream cause, acetylcholinesterase inhibition. The framework applies at synapses and neuromuscular junctions.
The same accumulation mechanism can have different significance depending on its source. Therapeutic cholinesterase inhibitors use acetylcholinesterase inhibition as part of a drug action, whereas organophosphate and carbamate compounds are associated with toxic effects. Comparing these contexts helps pharmacologists separate intended modulation of cholinergic signaling from accumulation linked to toxicant exposure.
Cholinergic symptoms can be interpreted as consequences of prolonged stimulation rather than as isolated receptor events. When acetylcholinesterase inhibition permits acetylcholine to persist, muscarinic and nicotinic receptors receive continued signaling at relevant target sites. Connecting symptoms to this upstream process helps organize pharmacological observations around disrupted cholinergic transmission and receptor overactivation.
Pharmacologists use the mechanism to relate a drug's effect to acetylcholinesterase inhibition and the resulting persistence of acetylcholine. This is especially relevant when examining therapeutic cholinesterase inhibitors, because the framework links the intended drug action with changes in cholinergic signaling. It also supports comparison with organophosphate and carbamate toxicity when interpreting unwanted effects.
Restoring balanced neurotransmission addresses the central problem created by sustained cholinergic stimulation. Treatment development can therefore focus on countering the consequences of acetylcholine persistence rather than considering symptoms independently from their biochemical cause. In pharmacology, this perspective guides efforts to develop interventions that bring signaling at synapses and neuromuscular junctions back toward an appropriate level.